The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease (Q38052955)

27 August 2017

title

The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease (English)

1 reference

chronic obstructive pulmonary disease

27 August 2017

main subject

1 reference

François Maltais

1 reference

27 August 2017

Julie Milot

series ordinal

1 reference

27 August 2017

publication date

17 October 2012

1 reference

Therapeutic advances in respiratory disease

27 August 2017

published in

1 reference

27 August 2017

1 reference

27 August 2017

1 reference

27 August 2017

page(s)

345-361

1 reference

Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Characterisation of COPD heterogeneity in the ECLIPSE cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Night-time symptoms: a forgotten dimension of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Identification of the human enzymes responsible for the enzymatic hydrolysis of aclidinium bromide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Factors determining constant work rate exercise tolerance in COPD and their role in dictating the minimal clinically important difference in response to interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Outcomes for COPD pharmacological trials: from lung function to biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Aclidinium bromide provides long-acting bronchodilation in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

The Genuair® inhaler: a novel, multidose dry powder inhaler

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Pharmacokinetics and safety of aclidinium bromide in younger and elderly patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Ba 679 BR, a novel long-acting anticholinergic bronchodilator

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Chronic obstructive pulmonary disease: the disease and its burden to society

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Peak inspiratory flow through the Genuair inhaler in patients with moderate or severe COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

The MCID of the transition dyspnea index is a total score of one unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Lung deposition of aclidinium bromide from Genuair, a multidose dry powder inhaler.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Safety and Tolerability of Aclidinium Administered Intravenously and Absolute Bioavailability of Inhaled Aclidinium in Healthy Male Participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

COPD heterogeneity: what this will mean in practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: A phase I, open-label, single-dose clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Symptom variability in patients with severe COPD: a pan-European cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812463626

21 January 2018

Identifiers

DOI

10.1177/1753465812463626

1 reference

27 August 2017

1 reference